Application of tripterine to preparation of medicine treating degenerative retinopathy related diseases

A technology of tripterine and retinal degeneration, applied to metabolic diseases, sensory diseases, drug combinations, etc., to achieve remarkable results

CN105343107AInactive Publication Date: 2016-02-24YUEYANG INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL SHANGHAI UNIV OF CHINESE TRADITIONAL MEDICINE +1
3 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2016-02-24
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to application of tripterine to preparation of medicine treating degenerative retinopathy related diseases. A mouse model suffering from retinal photodamage is adopted to simulate a common pathological link in various degenerative retinopathy generation processes, that is, death of photoreceptor cells; the photoreceptor cell death preventing function and the degenerative retinopathy preventing function of tripterine are researched, wherein the results show that tripterine can be used for inhibiting mass dead of the photoreceptor cells and structural damage and functional injury of a retina caused by photodamage, and is very obvious in degenerative retinopathy treating effect. Therefore, tripterine can be used for preparing medicine treating various types of degenerative retinopathy including age related macular degeneration, retinitis pigmentosa, Stargardt disease, cone-rod dystrophy, diabetic retinopathy and the like, or preparation of reagents used in related scientific researches.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the new medical application of the compound, specifically, relates to the preparation and prevention of Celastrol in the preparation and prevention of retinal photoreceptor cell death as the core pathology including age-related macular degeneration, Stargardt disease, cone-rod cell The application of drugs for retinal degenerative diseases including malnutrition, retinitis pigmentosa and diabetic retinopathy. Background technique

[0002] Retinal degenerative diseases with retinal photoreceptor cell death as the core pathology include age-related macular degeneration, Stargardt disease, cone-rod cell dystrophy, retinitis pigmentosa and diabetic retinopathy, etc., which can cause severe visual impairment Even blindness.

[0003] Age-related macular degeneration is one of the most common major types of retinal degenerative diseases that seriously endanger vision health and even cause blindness worldwide. Epidemiological...

Examples

Embodiment 1

[0047] In this embodiment, we have clarified the intervention effect of tripterine on the retinal photodamage mouse model through non-invasive retinal fundus optical coherence tomography OCT technology and immunohistochemical staining. The research results show that tripterine can effectively interfere with the death of photoreceptor cells and the occurrence of retinal degeneration, and have a significant protective effect on the structure of the retina.

[0048] 1. Method

[0049] 1. Drug: tripterine, purchased from Sigma (C0869, Lot#113M4601V and Lot#042M4608V), with a purity of ≥98%.

[0050] 2. Animal model: 4-6 weeks old female Balb / c mice (Slack, Shanghai) were used for experiments. Mice were randomly divided into normal control group, photodamage model control group and Celastrol treatment group, with 8 mice in each group. The normal control group did not receive white light stimulation, but only received solvent DMSO treatment, and the other groups received 50 μl sol...